Provided by Tiger Fintech (Singapore) Pte. Ltd.

Merck

94.65
+0.65000.69%
Post-market: 94.900.2500+0.26%19:54 EST
Volume:24.10M
Turnover:2.30B
Market Cap:239.09B
PE:14.04
High:97.37
Open:94.26
Low:93.85
Close:94.00
Loading ...

Health Canada Approves Merck's Keytruda® (Pembrolizumab) for the Treatment of Adult Patients With Resectable Stage Ii, Iiia, or Iiib (T3-4N2) Non-Small Cell Lung Carcinoma (Nsclc) in Combination With Platinum-Containing Chemotherapy as Neoadjuvant Treatment, and Then Continued as Monotherapy as Adjuvant Treatment After Surgery

THOMSON REUTERS
·
11 Feb

Health Canada Approves Merck's KEYTRUDA® (pembrolizumab) for the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) non-small cell lung carcinoma (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery

CNW Group
·
11 Feb

Buy Rating on Springworks Therapeutics Driven by Potential Merck Acquisition and Strong Drug Market Potential

TIPRANKS
·
11 Feb

German Merck's Potential Buy of SpringWorks Therapeutics Holds Profitability Risk -- Market Talk

Dow Jones
·
11 Feb

Merck (MRK) Downgraded by TD Cowen Over Keytruda, Gardasil Concerns

Insider Monkey
·
11 Feb

Pfizer, Astellas Cite 'Durable Benefit' in More Trial Results of Padcev Plus Keytruda in Urothelial Cancer

MT Newswires Live
·
11 Feb

Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)

Business Wire
·
11 Feb

PRESS RELEASE: Eqs-Adhoc: Merck Kgaa Confirms Discussions With Springworks Therapeutics, Inc. On Potential Acquisition

Dow Jones
·
11 Feb

BUZZ-TD Cowen cuts Merck to 'hold' on weak forecast and HPV vaccine troubles

Reuters
·
10 Feb

Top Calls on Wall Street: Nvidia, Tesla, Mobileye, Arm, Amazon, Disney, Home Depot & More

Tiger Newspress
·
10 Feb

TD Cowen cuts Merck stock to hold on uncertainty around Keytruda, Gardasil

Investing.com
·
10 Feb

TD Cowen Downgrades Merck & Co. to Hold From Buy, Adjusts Price Target to $100 From $121

MT Newswires Live
·
10 Feb

Merck & Co Inc : TD Cowen Cuts to Hold From Buy

THOMSON REUTERS
·
10 Feb

Better High-Yield Dividend Stock: Pfizer vs. Merck

Motley Fool
·
10 Feb

2 Biotech Stocks to Buy Hand Over Fist in February

Motley Fool
·
09 Feb

Is Summit Therapeutics a Millionaire Maker?

Motley Fool
·
09 Feb